Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma.
Prashant Bavi,Shahab Uddin,Maqbool Ahmed,Zeenath Jehan,Rong Bu,Jehad Abubaker,Mehar Sultana,Nasser Al-Sanea,Alaa Abduljabbar,Luai H. Ashari,Samar Alhomoud,Fouad Al-Dayel,Sarita Prabhakaran,Azhar R. Hussain,Khawla S. Al-Kuraya +14 more
Reads0
Chats0
TLDR
The results suggest that UBE2C and the ubiquitin-proteasome pathway may be potential targets for therapeutic intervention in CRC.Abstract:
Substantial evidence implicates the ubiquitin-conjugating enzyme E2C (UBE2C) gene, in several human cancers, including colorectal carcinoma (CRC). We therefore investigated the prognostic value of UBE2C alterations in CRC and UBE2C signaling in CRC cell lines. UBE2C protein expression and UBE2C gene copy number were evaluated on clinical samples by immunohistochemistry and fluorescence in situ hybridization in a TMA format. The effect of the proteasome inhibitor bortezomib and small-interfering RNA knockdown was assessed by apoptotic assays and immunoblotting. UBE2C dysregulation was associated with proliferative marker Ki-67, accumulation of cyclin A and B1, and a poor overall survival. UBE2C expression was an independent prognostic marker in early-stage (I and II) CRC. UBE2C depletion resulted in suppression of cellular growth and accumulation of cyclin A and B1. In vitro, bortezomib treatment of CRC cells caused inhibition of cell viability via down-regulation of UBE2C. UBE2C knockdown by bortezomib or transfection with specific small-interfering RNA against UBE2C also caused cells to be arrested at the G2/M level, leading to accumulation of cyclin A and cyclin B1. In vivo, a significant reduction in tumor volume and weight was noted in mice treated with a combination of subtoxic doses of oxaliplatin and bortezomib compared with treatment with oxaliplatin or bortezomib alone. Altogether, our results suggest that UBE2C and the ubiquitin-proteasome pathway may be potential targets for therapeutic intervention in CRC.read more
Citations
More filters
Journal ArticleDOI
Ten hub genes associated with progression and prognosis of pancreatic carcinoma identified by co-expression analysis.
TL;DR: All real hub genes were overexpressed in pancreatic carcinoma compared with normal tissues on transcriptional and translational level and both functional enrichment analysis and gene set enrichment was performed and both showed the cell cycle played a vital role in PDAC.
Journal ArticleDOI
Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker
TL;DR: This minireview summarizes what is known about the function of UBE2C focusing on its role in the regulation of spindle assembly checkpoint, its part in tumorigenesis, and its potential as a tumor marker for various cancers.
Journal ArticleDOI
Therapeutic targeting of cancer cell cycle using proteasome inhibitors.
TL;DR: Some of the signaling pathways related to proteasome inhibition and cell division that may help explain the basis of resistance of some cancers to proteAsome inhibitors are discussed and the need for usage of PIs in combination with traditional chemotherapy is underlined.
Journal ArticleDOI
Identification of Candidate Biomarkers Correlated With the Pathogenesis and Prognosis of Non-small Cell Lung Cancer via Integrated Bioinformatics Analysis
Mengwei Ni,Xinkui Liu,Jiarui Wu,Dan Zhang,Jinhui Tian,Ting Wang,Shuyu Liu,Ziqi Meng,Kaihuan Wang,Xiaojiao Duan,Wei Zhou,Xiaomeng Zhang +11 more
TL;DR: The results showed that TOP2A, CCNB1, CCNA2, UBE2C, KIF20A, and IL-6 may be potential key genes, while the mitotic cell cycle pathway may be a potential pathway contribute to progression in NSCLC.
Journal ArticleDOI
Targeting Neuroblastoma Stem Cells with Retinoic Acid and Proteasome Inhibitor
Barbara Hämmerle,Yania Yáñez,Sarai Palanca,Adela Cañete,Deborah J. Burks,Victoria Castel,Jaime Font de Mora +6 more
TL;DR: The results suggest that dual therapy of RA and proteasome inhibitor might be beneficial for targeting the side-population of cells associated residual disease in high-risk neuroblastoma.
References
More filters
Journal ArticleDOI
X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
TL;DR: A graphical method is developed, the X-tile plot, that illustrates the presence of substantial tumor subpopulations and shows the robustness of the relationship between a biomarker and outcome by construction of a two dimensional projection of every possible subpopulation.
Journal ArticleDOI
Themes and variations on ubiquitylation.
TL;DR: It is shown that the conjugation of proteins with a small protein called ubiquitin touches upon all aspects of eukaryotic biology, and its defective regulation is manifest in diseases that range from developmental abnormalities and autoimmunity to neurodegenerative diseases and cancer.
Journal Article
Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.
TL;DR: A monoclonal antibody against estrogen receptor (H222 Sp gamma) was used on cryostat sections of freshly frozen breast tumors with a peroxidase-antiperoxidases immunoperoxid enzyme technique to study sensitivity and specificity of estrogen receptor in patients treated with hormonal therapy.
Journal ArticleDOI
Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer
Herbert Hurwitz,Louis Fehrenbacher,John D. Hainsworth,W. Heim,Jordan Berlin,Eric Holmgren,Julie Hambleton,William Novotny,Fairooz F. Kabbinavar +8 more
TL;DR: The FU/LV/BV regimen seems as effective as IFL and has an acceptable safety profile, and is an active alternative treatment regimen for patients with previously untreated metastatic CRC.
Journal ArticleDOI
The ubiquitin-proteasome system.
TL;DR: The key observations that led to the discovery of ubiquitin-proteasome system (UPS) are recounted and some key roles of the UPS in different areas of biology and the use of inhibitors of this pathway as possible drug targets are discussed.